William Blair analyst Matt Phipps has maintained their bullish stance on INKT stock, giving a Buy rating today.
Matt Phipps has given his Buy rating due to a combination of factors including the promising developments in MiNK Therapeutics’ clinical trials and strategic plans. The ongoing Phase II study of agenT-797 in gastric cancer, conducted by Memorial Sloan Kettering, is progressing well with most patients already enrolled, indicating a robust pipeline and potential positive outcomes.
Additionally, MiNK’s strategic plan to present clinical updates in 2025 and initiate new studies, such as the Phase I study for agenT-797 in steroid-refractory acute conditions, reflects a proactive approach to expanding their therapeutic offerings. These factors suggest a strong potential for growth and innovation, supporting the Buy rating for MiNK Therapeutics’ stock.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.